Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17300780 | 0.85 | HRH4 (0.42) | CCNT1CDK9 | |
| SCHEMBL17300778 | 0.84 | HRH3 (0.34) | MAP3K12CCNT1CDK9PTGS1PTGS2 | |
| SCHEMBL19171756 | 0.82 | CCNT1 (0.35) | MAP3K12CCNT1CDK9RXRAGRIN1 | |
| SCHEMBL17300768 | 0.80 | CCNT1 (0.38) | MAP3K12CCNT1CDK9 | |
| SCHEMBL17300831 | 0.77 | PTGS2 (0.32) | CCNT1CDK9PTGS2 | |
| SCHEMBL17306680 | 0.77 | CCNT1 (0.32) | CCNT1CDK9 | |
| SCHEMBL17300821 | 0.77 | HMGCR (0.33) | CCNT1CDK9HMGCR | |
| SCHEMBL17300783 | 0.76 | CCNT1 (0.33) | CCNT1CDK9HMGCR | |
| SCHEMBL17300790 | 0.75 | PDE4A (0.40) | CCNT1CDK9PTGS2 | |
| SCHEMBL17300802 | 0.74 | HRH4 (0.42) | CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | MAP3K12 1295/4885CCNT1 1352/4885CDK9 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.